The IMAGINE Study: An Investigational Therapy to Treat Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients

Clinical Trial Title

This is a clinical trial evaluating the safety and efficacy of investigational drug for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients

National Clinical Trial Number:


Contact Information

Clinical Trial Protocol Description:

This is a clinical research study investigating an experimental drug vs placebo in the treatment of chronic active antibody-mediated rejection. The experimental drug is a subcutaneous injection administered every 4 weeks. Subjects are asked to come in for regularly scheduled research visits at the RUSH downtown campus.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are a living donor or deceased donor kidney transplant recipient greater than 6 months from time of transplant.
  • Have a diagnosis of chronic active antibody-mediated rejection and the presence of human leukocyte antigen (HLA) DSA.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Vasil Peev, MD

Contact Information

Diana Goldman

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more